• search

Connect with our scientific experts for your drug discovery, development, and manufacturing needs

We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.

Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.

Country

section

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

rightCaptcha

Immuno-Oncology: Therapies and Challenges Immuno-Oncology: Therapies and Challenges

Immuno-Oncology: 
Therapies and Challenges

Explore the latest breakthroughs in this revolutionary field

Read our insightful whitepaper

by Shalini Tanwar | Team lead - In Vitro Biology (NBE-Oncology) at APSL

White Paper

Country
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

How is Immuno-Oncology    
breaking barriers in cancer care?

  • Immuno-oncology: An emerging field in cancer diagnosis and treatment
  • Rapid advances in Immuno-oncology: Novel treatment combinations and newly identified targets
  • Immuno-oncology: Therapies and challenges
  • Diverse modalities in immunotherapy: mAbs, bifunctional agents, epigenetic modulators,vaccines, Adoptive-T-cell therapy, nanoparticles, oncolytic viruses and synthetic gene circuits.
  • Immuno-oncology modalities for hard to treat tumors
  • Adoptive T cell transfer (ATC) therapy
  • Bispecific antibodies
  • Immune checkpoint inhibitors and combination therapies
  • Cancer vaccines
  • Aurigene: Immuno-oncology services
author

Author’s bio

Shalini Tanwar is an accomplished cellular immunologist specializing in cellular crosstalk during inflammation, autoimmunity, and immuno-oncology. With over 12 years of experience, she excels in designing and executing complex immune assays.

Shalini’s impressive achievements include validating experiments for immune cell redirection, expanding GD-T-cell populations by 300-fold, and uncovering the crosstalk between Treg cells and MDSCs. Currently serving as Team lead - In Vitro Biology (NBE-Oncology) at Aurigene, her expertise, and leadership in the field make her an invaluable asset in advancing research and development in the exciting and rapidly evolving field of immuno-oncology.

Download the whitepaper

About Aurigene

Aurigene Pharmaceutical Services Ltd. is a globally recognized contract research, development, and manufacturing organization (CDMO) that actively contributes to the advancement of pharmaceutical innovation. With a steadfast commitment to thought leadership, we offer comprehensive and integrated solutions to empower visionary companies in expediting their products from laboratory to market.    

At Aurigene, we seamlessly blend our extensive knowledge, experience, and cutting-edge technology to catalyze the progress of our clients' groundbreaking endeavours. Our unwavering dedication to innovation is underscored by our world-class research and development centres in India, boasting a team of over 650 exceptional scientists. These centres are fortified by state-of-the-art commercial manufacturing facilities strategically located in India, the United Kingdom, Mexico, and the United States.

Fueling biologics advancements    
with cutting-edge NBE services

Aurigene Pharmaceutical Services provides a wide range of high-quality and flexible scale development and manufacturing services for Biotherapeutics and Viral vectors. We are expanding our Biotherapeutics services, with a focus on mono-clonal antibodies(mAbs), therapeutic proteins and viral vectors. We are developing a facility which will meet the process development and clinical supplies needs of global biotech companies. The new facility is based on a state-of-the-art design concept, allowing maximum flexibility for a multi-product, multi-platform offering across proteins, mAbs, and viral vectors. We offer exclusive access to an established large-scale GMP manufacturing facility with a drug substance capacity of 15kl and fill-finish capabilities making it possible to provide commercial quantities seamlessly.

Fueling biologics advancements with NBE services

Share your details to download our whitepaper

Country
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack